A Novel Sequential Regimen of Efgartigimod and Telitacicept as Fast-Acting Treatment for Impeding Crisis of MuSK-MG.

Authors

Tianjiao Duan, Song Ouyang, Wei Lu, Weifan Yin

Published in

Immunity, inflammation and disease. Volume 14. Issue 10. Pages e70521.

Abstract

Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction. The muscle-specific kinase (MuSK) antibody-positive subtype often involves bulbar and respiratory muscles, conferring a high risk of myasthenic crisis.
We report a very late-onset MuSK-MG case complicated by lung infection and acute heart failure, with a history of peptic ulcer. The patient was sequentially treated with efgartigimod and telitacicept, achieving minimal symptom expression (MSE) within 1.5 months.
Following the first efgartigimod infusion, QMG and MG-ADL scores improved from 31 to 23 and 22 to 12, respectively. After five injections of telitacicept, symptoms resolved completely on day 47, with scores further reducing to 2 (QMG) and 0 (MG-ADL). Treatment also reduced IgG levels and MuSK-Ab titers, while IgM remained stable.
This case demonstrates the successful sequential use of efgartigimod and telitacicept in managing complicated, late-onset MuSK-MG in a state of impeding crisis.

PMID:
42853026
Bibliographic data and abstract were imported from PubMed on 09 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.